Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023
31 Julio 2023 - 7:00AM
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology
company focused on development of targeted therapies for oncology,
today announced that Brian Sullivan, Chairman, Chief Executive
Officer, and Co-founder of Celcuity, will participate in one-on-one
meetings at the BTIG Virtual Biotechnology Conference being held on
August 7-8, 2023.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on
development of targeted therapies for treatment of multiple solid
tumor indications. The company's lead therapeutic candidate is
gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism
of action and pharmacokinetic properties are highly differentiated
from other currently approved and investigational therapies that
target PI3K or mTOR alone or together. A Phase 3 clinical trial,
VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant
with or without palbociclib in patients with HR+/HER2- advanced
breast cancer is currently enrolling patients. More detailed
information about the VIKTORIA-1 study can be found at
ClinicalTrials.gov. The company's CELsignia companion diagnostic
platform is uniquely able to analyze live patient tumor cells to
identify new groups of cancer patients likely to benefit from
already approved targeted therapies. Further information about
Celcuity can be found at Celcuity.com. Follow us
on LinkedIn and Twitter.
Contacts:
Celcuity Inc.Brian Sullivan, bsullivan@celcuity.comVicky Hahne,
vhahne@celcuity.com(763) 392-0123
ICR WestwickeRobert Uhl, robert.uhl@westwicke.com
(619) 228-5886
Celcuity (NASDAQ:CELC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Celcuity (NASDAQ:CELC)
Gráfica de Acción Histórica
De May 2023 a May 2024